| Peer-Reviewed

Cardio-Cerebral Infarction Syndrome (CCIS): Definition, Diagnosis, Pathophysiology and Treatment

Received: 15 May 2021    Accepted: 29 May 2021    Published: 7 June 2021
Views:       Downloads:
Abstract

Acute ischemic stroke (AIS) and coronary artery disease are the major causes of death in Palestine and in the world. Ischemic stroke and acute coronary syndrome have similar vascular risk factors and may evolve as a complication of the respective other disease. The prevalence of coronary artery disease has been reported in one fifth of stroke patients. high incidence rate of acute myocardial infarction (AMI) after recent ischemic stroke and the high risk of acute ischemic stroke after recent myocardial infarction has been reported in several clinical or observational studies. Patients are at increased risk of ischemic stroke following recent myocardial infarction, and aggressive treatment of AMI, including use of reperfusion therapy, decreases the risk of AIS. For patients presenting with AIS in the setting of a recent MI, treatment with alteplase, an intravenous tissue plasminogen activator, can be given, but may be harmful in many conditions. It is important for clinicians to recognize that troponin elevations can occur in the setting of AIS as well as other clinical scenarios and that this may have implications for short- and long-term mortality. So that acute or recent problem in the heart or brain that could result in an acute infarction of the other. In this review we describe the definition and new classification of the cardio-cerebral infarction syndrome with 3 subtypes that reflect the definition, pathophysiology and treatment options.

Published in Cardiology and Cardiovascular Research (Volume 5, Issue 2)
DOI 10.11648/j.ccr.20210502.15
Page(s) 78-87
Creative Commons

This is an Open Access article, distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution and reproduction in any medium or format, provided the original work is properly cited.

Copyright

Copyright © The Author(s), 2024. Published by Science Publishing Group

Keywords

Cardio-cerebral Infarction Syndrome (CCIS), Diagnosis, Pathophysiology and Treatment

References
[1] Al Suwaidi J, Al Habib K, Asaad N, Singh R, Hersi A, Al Falaeh H, et al. Immediate and one-year outcome of patients presenting with acute coronary syndrome complicated by stroke: findings from the 2nd Gulf Registry of Acute Coronary Events (Gulf RACE-2). BMC Cardiovasc Disord. 2012; 12: 64.
[2] Longstreth WT Jr, Litwin PE, Weaver WD. Myocardial infarction, thrombolytic therapy, and stroke. A community-based study. The MITI Project Group. Stroke. 1993; 24: 587–590.
[3] Kajermo U, Ulvenstam A, Modica A, Jernberg T, Mooe T. Incidence, trends, and predictors of ischemic stroke 30 days after an acute myocardial infarction. Stroke. 2014; 45: 1324–1330.
[4] Mooe T, Olofsson BO, Stegmayr B, Eriksson P. Ischemic stroke. Impact of a recent myocardial infarction. Stroke. 1999; 30: 997–1001.
[5] Brammås A, Jakobsson S, Ulvenstam A, Mooe T. Mortality after ischemic stroke in patients with acute myocardial infarction: predictors and trends over time in Sweden. Stroke. 2013; 44: 3050–3055.
[6] Brandi J. Witt, MD et al. The Incidence of Stroke after Myocardial Infarction: A Meta-Analysis. The American Journal of Medicine (2006) 119, 354. e1-354.
[7] Keon-Joo Lee, MD et al. Five-Year Risk of Acute Myocardial Infarction After Acute Ischemic Stroke in Korea. J Am Heart Assoc. 2021; 10: e018807. DOI: 10.1161/JAHA.120.0188.
[8] Leonard L L Yeo et al. Synchronous cardiocerebral infarction in the era of endovascular therapy: which to treat first? J Thromb Thrombolysis 2017 Jul; 44 (1): 104-111. doi: 10.1007/s11239-017-1484-2.
[9] Tokuda K, Shindo S, Yamada K, Shirakawa M, Uchida K, Horimatsu T, et al. Acute embolic cerebral infarction and coronary artery embolism in a patient with atrial fibrillation caused by similar thrombi. J Stroke Cerebrovasc Dis (2016) 25: 1797–9. doi: 10.1016/j.jstrokecerebrovasdis.2016.01.055.
[10] Nguyen TL, Rajaratnam R. Dissecting out the cause: a case of concurrent acute myocardial infarction and stroke. BMJ Case Rep (2011) 2011: bcr0220113824. doi: 10.1136/bcr.02.2011.3824 17.
[11] Verma GC, Jain G, Wahid A, Saurabh C, Sharma NK, Pathan AR, et al. Acute ischaemic stroke and acute myocardial infarction occurring together in domestic low-voltage (220-240V) electrical injury: a rare complication. J Assoc Physicians India (2014) 62: 620–3.
[12] Yeo LL, Andersson T, Yee KW, Tan BY, Paliwal P, Gopinathan A, et al. Synchronous cardiocerebral infarction in the era of endovascular therapy: which to treat first? J Thromb Thrombolysis (2017) 44: 104–11. doi: 10.1007/ s11239-017-1484-2 11.
[13] Omar HR, Fathy A, Rashad R, Helal E. Concomitant acute right ventricular infarction and ischemic cerebrovascular stroke; possible explanations. Int Arch Med (2010) 3: 25. doi: 10.1186/755-7682-3-25.
[14] Nagai M, Hoshide S, Kario K. The insular cortex and cardiovascular system: a new insight into the brain-heart axis. J Am Soc Hypertens (2010) 4: 174–82. doi: 10.1016/j.jash.2010.05.001.
[15] Vingerhoets F, Bogousslavsky J, Regli F, Van Melle G. Atrial fibrillation after acute stroke. Stroke (1993) 24: 26–30. doi: 10.1161/01.STR.24.1.26.
[16] Christensen H, Boysen G, Christensen AF, Johannesen HH. Insular lesions, ECG abnormalities, and outcome in acute stroke. J Neurol Neurosurg Psychiatry (2005) 76: 269–71. doi: 10.1136/jnnp.2004.037531.
[17] Ay H, Koroshetz WJ, Benner T, Vangel MG, Melinosky C, Arsava EM, et al. Neuroanatomic correlates of stroke-related myocardial injury. Neurology (2006) 66: 1325–9. doi: 10.1212/01.wnl.0000206077.13705.
[18] Cheshire WP Jr, Saper CB. The insular cortex and cardiac response to stroke. Neurology (2006) 66: 1296–7. doi: 10.1212/01.wnl.0000219563.87204.
[19] Daniel Modin, MB et al. Acute COVID-19 and the Incidence of Ischemic Stroke and Acute Myocardial Infarction. Circulation. 2020; 142: 2080–2082. DOI: 10.1161/CIRCULATIONAHA.120.0508.
[20] Powers WJ, Rabinstein AA, Ackerson T, Adeoye OM, Bambakidis NC, Becker K, et al; American Heart Association Stroke Council. 2018 Guidelines for the early management of patients with acute ischemic stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2018; 49: e46–e110. doi: 10.1161/STR.0000000000000158.
[21] João Pedro Marto, MD et al. Intravenous Thrombolysis for Acute Ischemic Stroke After Recent Myocardial Infarction Case Series and Systematic Review. (Stroke. 2019; 50: 2813-2818. DOI: 10.1161/STROKEAHA.119.025630).
[22] Greaves SC, Zhi G, Lee RT, et al: Incidence and natural history of left ventricular thrombus following anterior wall acute myocardial infarction. Am J Cardiol 1997; 80: 442–448.
[23] Motro M, Barbash GI, Hod H, et al: Incidence of left ventricular thrombi formation after thrombolytic therapy with recombinant tissue plasminogen activator, heparin, and aspirin in patients with acute myocardial infarction. Am Heart J 1991; 122: 23–26.
[24] Lombardo A, Biasucci LM, Lanza GA, et al: inflammation possible link between coronary and carotid plaque instability. Circulation 2004; 109: 3158-3163.
[25] Yusuf S, Flather M, Pogue J, et al: Variations between countries in invasive cardiac proce-dures and outcomes in patients with suspect-ed unstable angina or myocardial infarction without initial ST elevation. OASIS Registry investigators. Lancet 1998; 352: 507–514.
[26] Healey JS, Connolly SJ, Gold MR, Israel CW, Van Gelder IC, Capucci A, et al; ASSERT Investigators. Subclinical atrial fibrillation and the risk of stroke. N Engl J Med. 2012; 366: 120–129.
[27] Eivind Berge et al. European Stroke Organisation (ESO) guidelines on intravenous thrombolysis for acute ischaemic stroke. European Stroke Journal 2021 http://dx.doi.org/10.1177/2396987321989865.
[28] Taku Inohara, MD, PhD et al. Recent Myocardial Infarction is Associated With Increased Risk in Older Adults With Acute Ischemic Stroke Receiving Thrombolytic Therapy. (J Am Heart Assoc. 2019; 8: e012450. DOI: 10.1161/JAHA.119.012450).
[29] Jean-Philippe Collet, et al. 2020 Acute Coronary Syndromes (ACS) in Patients Presenting without Persistent ST-Segment Elevation (Management of) Guidelines. European Heart Journal (2021) 42, 12891367.
[30] C. Michael Gibson et al. Prevention of Bleeding in Patients with Atrial Fibrillation Undergoing PCI. N Engl J Med 2016; 375: 2423-34.6.
[31] Paulus Kirchhof et al. 2016 ESC Guidelines for the management of atrial fibrillation. European Journal of Cardio-Thoracic Surgery 50 (2016) e1–e8.
[32] Cholesterol Treatment Trialists’ (CTT) Collaborators Kearney PM, Blackwell L, Collins R, Keech A, Simes J, Peto R, Armitage J, Baigent C. Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomisedtrials of statins: a meta-analysis. Lancet 2008; 371: 117125.534.
[33] Cholesterol Treatment Trialists’ (CTT) Collaboration Baigent C, Blackwell L, Emberson J, Holland LE, Reith C, Bhala N, Peto R, Barnes EH, Keech A, Simes J, Collins R. Efficacy and safety of more intensive lowering of LDL cholesterol: ameta-analysis of data from 170,000 participants in 26 randomised trials. Lancet 2010; 376: 16701681.535.
[34] Sabatine MS, Giugliano RP, Keech AC, Honarpour N, Wiviott SD, Murphy SA, Kuder JF, Wang H, Liu T, Wasserman SM, Sever PS, Pedersen TR, FOURIER Steering Committee and Investigators. Evolocumab and clinical outcomes inpatients with cardiovascular disease. N Engl J Med 2017; 376: 17131722.536.
[35] Flather MD, Yusuf S, Kober L, Pfeffer M, Hall A, Murray G, Torp-Pedersen C, Ball S, Pogue J, Moye L, Braunwald E. Long-term ACE-inhibitor therapy inpatients with heart failure or left-ventricular dysfunction: a systematic over view of data from individual patients. ACE-Inhibitor Myocardial Infarction Collaborative Group. Lancet 2000; 355: 15751581.537.
[36] SOLVD Investigators Yusuf S, Pitt B, Davis CE, Hood WB, Cohn JN. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991; 325: 293302.538.
[37] Leizorovicz A, Lechat P, Cucherat M, Bugnard F. Bisoprolol for the treatment of chronic heart failure: a meta-analysis on individual data of two placebo-controlled studies CIBIS and CIBIS II. Cardiac Insufficiency Bisoprolol Study. Am Heart J 2002; 143: 301307.540.
[38] Packer M, Bristow MR, Cohn JN, Colucci WS, Fowler MB, Gilbert EM, Shusterman NH. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group. N Engl JMed 1996; 334: 13491355.541.
[39] Poole-Wilson PA, Swedberg K, Cleland JG, Di Lenarda A, Hanrath P, KomajdaM, Lubsen J, Lutiger B, Metra M, Remme WJ, Torp-Pedersen C, Scherhag A, Skene A, Carvedilol Or Metoprolol European Trial Investigators. Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomized controlled trial. Lancet 2003; 362: 713.542.
[40] Kernis SJ, Harjai KJ, Stone GW, Grines LL, Boura JA, O’Neill WW, Grines CL. Does beta-blocker therapy improve clinical outcomes of acute myocardial infarction after successful primary angioplasty? JAmCollCardiol 2004; 43: 17731779.547.
[41] Bangalore S, Makani H, Radford M, Thakur K, Toklu B, Katz SD, DiNicolantonioJJ, Devereaux PJ, Alexander KP, Wetterslev J, Messerli FH. Clinical outcomes with beta-blockers for myocardial infarction: a meta-analysis of randomized trials. Am J Med 2014; 127: 939953.548.
[42] Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, Palensky J, WittesJ. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. NEngl J Med 1999; 341: 709717.549.
[43] Pitt B, Remme W, Zannad F, Neaton J, Martinez F, Roniker B, Bittman R, Hurley S, Kleiman J, Gatlin M, Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study Investigators. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003; 348: 13091321.
[44] Valgimigli M, Bueno H, Byrne RA, Collet JP, Costa F, Jeppsson A, Juni P, KastratiA, Kolh P, Mauri L, Montalescot G, Neumann FJ, Petricevic M, Roffi M, Steg PG, Windecker S, Zamorano JL, Levine GN, ESC Scientific Document Group, ESCCommittee for Practice Guidelines (CPG), ESC National Cardiac Societies. 2017 ESC focused update on dual antiplatelet therapy in coronary artery dis-ease developed in collaboration with EACTS: The Task Force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J 2018; 39: 213260.
Cite This Article
  • APA Style

    Mohammed Habib. (2021). Cardio-Cerebral Infarction Syndrome (CCIS): Definition, Diagnosis, Pathophysiology and Treatment. Cardiology and Cardiovascular Research, 5(2), 78-87. https://doi.org/10.11648/j.ccr.20210502.15

    Copy | Download

    ACS Style

    Mohammed Habib. Cardio-Cerebral Infarction Syndrome (CCIS): Definition, Diagnosis, Pathophysiology and Treatment. Cardiol. Cardiovasc. Res. 2021, 5(2), 78-87. doi: 10.11648/j.ccr.20210502.15

    Copy | Download

    AMA Style

    Mohammed Habib. Cardio-Cerebral Infarction Syndrome (CCIS): Definition, Diagnosis, Pathophysiology and Treatment. Cardiol Cardiovasc Res. 2021;5(2):78-87. doi: 10.11648/j.ccr.20210502.15

    Copy | Download

  • @article{10.11648/j.ccr.20210502.15,
      author = {Mohammed Habib},
      title = {Cardio-Cerebral Infarction Syndrome (CCIS): Definition, Diagnosis, Pathophysiology and Treatment},
      journal = {Cardiology and Cardiovascular Research},
      volume = {5},
      number = {2},
      pages = {78-87},
      doi = {10.11648/j.ccr.20210502.15},
      url = {https://doi.org/10.11648/j.ccr.20210502.15},
      eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.ccr.20210502.15},
      abstract = {Acute ischemic stroke (AIS) and coronary artery disease are the major causes of death in Palestine and in the world. Ischemic stroke and acute coronary syndrome have similar vascular risk factors and may evolve as a complication of the respective other disease. The prevalence of coronary artery disease has been reported in one fifth of stroke patients. high incidence rate of acute myocardial infarction (AMI) after recent ischemic stroke and the high risk of acute ischemic stroke after recent myocardial infarction has been reported in several clinical or observational studies. Patients are at increased risk of ischemic stroke following recent myocardial infarction, and aggressive treatment of AMI, including use of reperfusion therapy, decreases the risk of AIS. For patients presenting with AIS in the setting of a recent MI, treatment with alteplase, an intravenous tissue plasminogen activator, can be given, but may be harmful in many conditions. It is important for clinicians to recognize that troponin elevations can occur in the setting of AIS as well as other clinical scenarios and that this may have implications for short- and long-term mortality. So that acute or recent problem in the heart or brain that could result in an acute infarction of the other. In this review we describe the definition and new classification of the cardio-cerebral infarction syndrome with 3 subtypes that reflect the definition, pathophysiology and treatment options.},
     year = {2021}
    }
    

    Copy | Download

  • TY  - JOUR
    T1  - Cardio-Cerebral Infarction Syndrome (CCIS): Definition, Diagnosis, Pathophysiology and Treatment
    AU  - Mohammed Habib
    Y1  - 2021/06/07
    PY  - 2021
    N1  - https://doi.org/10.11648/j.ccr.20210502.15
    DO  - 10.11648/j.ccr.20210502.15
    T2  - Cardiology and Cardiovascular Research
    JF  - Cardiology and Cardiovascular Research
    JO  - Cardiology and Cardiovascular Research
    SP  - 78
    EP  - 87
    PB  - Science Publishing Group
    SN  - 2578-8914
    UR  - https://doi.org/10.11648/j.ccr.20210502.15
    AB  - Acute ischemic stroke (AIS) and coronary artery disease are the major causes of death in Palestine and in the world. Ischemic stroke and acute coronary syndrome have similar vascular risk factors and may evolve as a complication of the respective other disease. The prevalence of coronary artery disease has been reported in one fifth of stroke patients. high incidence rate of acute myocardial infarction (AMI) after recent ischemic stroke and the high risk of acute ischemic stroke after recent myocardial infarction has been reported in several clinical or observational studies. Patients are at increased risk of ischemic stroke following recent myocardial infarction, and aggressive treatment of AMI, including use of reperfusion therapy, decreases the risk of AIS. For patients presenting with AIS in the setting of a recent MI, treatment with alteplase, an intravenous tissue plasminogen activator, can be given, but may be harmful in many conditions. It is important for clinicians to recognize that troponin elevations can occur in the setting of AIS as well as other clinical scenarios and that this may have implications for short- and long-term mortality. So that acute or recent problem in the heart or brain that could result in an acute infarction of the other. In this review we describe the definition and new classification of the cardio-cerebral infarction syndrome with 3 subtypes that reflect the definition, pathophysiology and treatment options.
    VL  - 5
    IS  - 2
    ER  - 

    Copy | Download

Author Information
  • Cardiology Department, Al-Shifa Hospital, Gaza, Palestine

  • Sections